<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01973101</url>
  </required_header>
  <id_info>
    <org_study_id>NP 217/2012</org_study_id>
    <nct_id>NCT01973101</nct_id>
  </id_info>
  <brief_title>Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix.</brief_title>
  <acronym>CIRCE</acronym>
  <official_title>Phase II, Prospective, Randomized, Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de S達o Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto do Cancer do Estado de S達o Paulo</source>
  <brief_summary>
    <textblock>
      The purpose of this phase II study is to determine the survival free disease of patients&#xD;
      diagnosed with invasive locally advanced carcinomas of uterine cervix treated with induction&#xD;
      chemotherapy with cisplatin and gemcitabine followed by chemoradiation and definitive&#xD;
      chemoradiation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>From the randomization until the end of the treatment - up to 36 month.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>36 month after the end of the treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional disease control rate</measure>
    <time_frame>36 month after the end of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and chronic toxicity in both arms</measure>
    <time_frame>From the randomization until the end of the treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 month after the end of the treatment.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Patients Diagnosed With Advanced Carcinoma of Uterine Cervix t</condition>
  <arm_group>
    <arm_group_label>Chemo-induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin plus Gemcitabine for 3 cycles followed by Cisplatin, radiotherapy and brachytherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatin, radiotherapy and brachytherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>50 mg/m2 - Day 1</description>
    <arm_group_label>Chemo-induction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000mg/m2 on day 1 and day 8.</description>
    <arm_group_label>Chemo-induction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Cisplatin 40 mg/m2 on day 1, day8, day15, day22, day 36 of radiotherapy period.</description>
    <arm_group_label>Chemo-induction</arm_group_label>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>45 Gy</description>
    <arm_group_label>Chemo-induction</arm_group_label>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy</intervention_name>
    <description>80 Gy</description>
    <arm_group_label>Chemo-induction</arm_group_label>
    <arm_group_label>Chemoradiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Advanced carcinoma of uterine cervix histological confirmed.&#xD;
&#xD;
          2. Indication for definitive chemoradiation treatment;&#xD;
&#xD;
          3. Measurable disease by RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)&#xD;
             criteria;&#xD;
&#xD;
          4. Age between 18 years old and 70 years old;&#xD;
&#xD;
          5. Adequate bone marrow and organ function defined by laboratory values;&#xD;
&#xD;
          6. Non evidence of disease in para-aortic lymph node;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with Chemotherapy or radiotherapy&#xD;
&#xD;
          2. Previous surgery for primary tumor;&#xD;
&#xD;
          3. Distant metastasis;&#xD;
&#xD;
          4. Performance status according to Eastern Cooperative Oncology Group greater than 2;&#xD;
&#xD;
          5. Peripheric neuropathy greater than grade 2 by National Cancer Institute Common&#xD;
             Toxicity Criteria for Adverse Events (NCI-CTCAE) version 3.0;&#xD;
&#xD;
          6. Significant Cardiac disease (history of and/or active disease);&#xD;
&#xD;
          7. Other treatment for cancer, including hormonotherapy;&#xD;
&#xD;
          8. Psychiatric or addictive disorders or other conditions that, in the opinion of the&#xD;
             investigator, would preclude the patient from meeting the study requirements;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Del Pilar Estevez Diz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto do Cancer do Estado de S達o Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Del Pilar Estevez Diz, MD</last_name>
    <phone>55 11 3893-2000</phone>
    <email>pesquisa.clinica@icesp.org.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>ICESP</name>
      <address>
        <city>S達o Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Del Pilar Estevez Diz, MD</last_name>
      <phone>55 11 3893-2000</phone>
      <email>pesquisa.clinica@icesp.org.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>October 22, 2013</study_first_submitted>
  <study_first_submitted_qc>October 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2013</study_first_posted>
  <last_update_submitted>July 14, 2014</last_update_submitted>
  <last_update_submitted_qc>July 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced carcinomas of uterine cervix</keyword>
  <keyword>Chemoradiation</keyword>
  <keyword>Chemo-induction</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

